Somatostatin analogue compounds

Details Somatostatin analogue compounds Somatostatin analogue compounds

2005-03-29

2005-03-29

Desai, Rita (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S278700

Reexamination Certificate

active

06872827

ABSTRACT:
Compounds having somatostatin activity of the following Formula I,wherein,R1is aryl, substituted-aryl, and aryl-(lower-alkyl)-;R2is lower alkyl, amino substituted lower alkyl, -carboxy-(lower-alkyl), -carbamic acid-(lower-alkyl) and -carboxy-(lower-alkyl)-aryl; andR3and R4are independently, lower-alkyl, aryl, substituted-aryl, (substituted-aryl)-(lower-alkyl)-, heteroaryl, (heteroaryl)-(lower-alkyl)-, substituted-heteroaryl, (substituted heteroaryl)-(lower-alkyl)-, heterocyclic, heterocyclic-(lower-alkyl)-, substituted-heterocyclic, (substituted-heterocylic)-(lower alkyl)-, -carboxy-(lower-alkyl), and -carboxy-(lower-alkyl)-aryl; or a pharmaceutically acceptable, ester, ether, or salt thereof; methods for their use; and preparation.

REFERENCES:
patent: 4016100 (1977-04-01), Suzuki et al.
patent: 4348384 (1982-09-01), Horikoshi et al.
patent: 4659774 (1987-04-01), Webb et al.
patent: 5120859 (1992-06-01), Webb
patent: 5283293 (1994-02-01), Webb
patent: 5367072 (1994-11-01), Webb
patent: 5371072 (1994-12-01), Webb et al.
patent: 5492895 (1996-02-01), Vlasuk et al.
patent: 5514777 (1996-05-01), Webb et al.
patent: 5534498 (1996-07-01), Brunck et al.
patent: 5597804 (1997-01-01), Webb et al.
patent: 5656600 (1997-08-01), Abelman et al.
patent: 5670479 (1997-09-01), Abelman et al.
patent: 5714580 (1998-02-01), Brunck et al.
patent: 5731413 (1998-03-01), Webb et al.
patent: 5739112 (1998-04-01), Brunck et al.
patent: 5795905 (1998-08-01), McCarthy et al.
patent: 5869454 (1999-02-01), Webb et al.
patent: 5883077 (1999-03-01), Brunck et al.
patent: 5886146 (1999-03-01), Vlasuk et al.
patent: 5955576 (1999-09-01), Vlasuk et al.
patent: 6025372 (2000-02-01), Yang et al.
patent: 6211195 (2001-04-01), Webb et al.
patent: 6255310 (2001-07-01), Webb et al.
patent: 6288060 (2001-09-01), Webb et al.
patent: 6316437 (2001-11-01), Hoffman et al.
patent: 6469166 (2002-10-01), Webb et al.
patent: 0365556 (1990-05-01), None
patent: 0627929 (1994-12-01), None
patent: 0664786 (1995-08-01), None
patent: 0675899 (1995-10-01), None
patent: 0684830 (1995-12-01), None
patent: 0790982 (1997-08-01), None
patent: 0863882 (1998-09-01), None
patent: 0882051 (1998-12-01), None
patent: 2355264 (2001-04-01), None
patent: 2002121194 (2002-04-01), None
patent: 8809796 (1988-12-01), None
patent: 9104247 (1991-04-01), None
patent: 9312076 (1993-06-01), None
patent: 9314779 (1993-08-01), None
patent: 9315756 (1993-08-01), None
patent: 9408941 (1994-04-01), None
patent: 9413693 (1994-06-01), None
patent: 9417817 (1994-08-01), None
patent: 9421673 (1994-09-01), None
patent: 9535280 (1995-12-01), None
patent: 9639400 (1996-12-01), None
patent: 9510527 (1997-04-01), None
patent: 9714684 (1997-04-01), None
patent: 9729109 (1997-08-01), None
patent: 9729110 (1997-08-01), None
patent: 9847903 (1998-10-01), None
patent: 9941216 (1999-08-01), None
patent: 0158878 (2001-08-01), None
patent: 0158879 (2001-08-01), None
patent: 03090677 (2003-11-01), None
patent: 2003090677 (2003-11-01), None
Brazeau et al., “Hypothalamic Polypeptide That Inhibits the Secretation of Immunoreactive Pituitary Growth Hormone,”Science 179:77-79 (1972).
Chen et al., “Design and Synthesis of a Series of Non-Peptide High-Affinity Human Corticotropin-Releasing Factor1Receptor Antagonists,”J. Med. Chem. 39(22):4358-4360 (1996).
Cheng and Prusoff, “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction,”Biochem. Pharmacol. 22:3099-3108 (1973).
Eppstein et al., Controlled-Release and Localized Targeting of Interferons, inDelivery Systems for Peptide DrugsDavis et al. (Eds.) New York: Tomlinson, Plenum Pub. Corp. pp. 277-283 (1986).
Eppstein et al., “Liposome-Encapsulated Muramyl Dipeptide Analogue”Int. J. Immunotherapy 11(2):115-126 (1986).
Feniuk, W. et al., “Characterization of somatostatin receptors in guinea-pig isolated ileum, vas deferens and right atrium,”Br. J. Pharmacol. 110:1156-1164 (1993).
Gabizon et al., Liposomes as in Vivo Carriers of Adriamycin: Reduced Cardiac Uptake and Preserved Antitumor Activity in Mice,Cancer Res. 42:4734-4739 (1982).
Garland S. L. and Dean P. M., “Design criteria for molecular mimics of fragments of the β-turn. 1. Cα atom analysis,”J. Comp. Aided Mole. Des. 13:469-483 (1999).
Gotfredsen et al., “Cellular Localization of Stable Solid Liposomes in the Liver of Rats,”Biochemical Pharmacology 32(22):3389-3396 (1983).
Hirschmann, R., “De Novo Design and Synthesis of Somatostatin Non-Peptide Peptidomimetics Utilizing β-D-Glucose as a Novel Scaffolding,”J. Am. Chem. Soc. 115(26):12550-12568 (1993).
Huang et al., “Synthesis and SAR of 8-Arylquinolines as Potent Coirticotropin-Releasing Factor1(CRF1) Receptor Antagonists,”Bioorg Med Chem Lett. 13(19):3375-3379 (2003).
Hunt, C.A., “Liposomes Disposition in Vivo: V. Liposome Stability in Plasma and Implications for Drug Carrier Function,”Biochemica et Biophysica Acta. 719:450-463 (1982).
Liapakis et al., “Identification of Ligand Binding Determinants in the Somatostatin Receptor Subtypes 1 and 2,”J. Biol. Chem. 271(34):20331-20339 (1996).
Lopez-Berestein et al., “Liposomal Amphotericin B for the Treatment of Systemic Fungal Infections in Patients with Cancer: A Preliminary Study,”J. Infect. Dis. 151(4):704-710 (1985).
Olson et al., “Characterization, Toxicity and Therapeutic Efficacy of Adriamycin Encapsulated in Liposomes,”Eur. J. Cancer Clin. Oncol. 18:167-176 (1982).
Patel, Y.C. and Srikant, C.B., “Subtype Selectivity of Peptide Analogs for All Five Cloned Human Somatostatin Receptors (hsstr 1-5),”Endocrinology 135(6):2814-2817 (1994).
Reisine, T. and Bell, G.I., “Molecular Biology of Somatostatin Receptors,”Endocrine Reviews 16(4):427-442 (1995).
Senior et al., “Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection,”Biochemica et Biophysica Acta. 839:1-8 (1985).
Webb et al., “Epidural haematoma presenting as polymorphic ventricular tachycardia,”Heart. 89(3):316 (2003).
Webb et al. “Quinazolines as Adenosine Receptor Antagonists: SAR and Selectivity for A2BReceptors,”Bioorg Med Chem. 11(1):77-85 (2003).
Webb et al. “The Utilization of a Unified Pharmacophore Query in the Discovery of New Antagonists of the Adenosine Receptor Family,”Bioorg Med Chem Lett. 10(1):31-34 (2000).
Weinstein et al., “Liposomes as Drug Carriers in Cancer Chemotherapy,”Pharmac. Ther. 24:207-233 (1983).
Whitten et al., “Rapid Microscale Synthesis, a New Method for Lead Optimization Using Robotics and Solution Phase Chemistry: Application to the Synthesis and Optimization of Corticotropin-Releasing Factor1Receptor Antagonists,”J. Med. Chem. 39(22):4354-4357 (1996).

Affiliated with

Also associated with

Rating

Somatostatin analogue compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Somatostatin analogue compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Somatostatin analogue compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3406803